NCT00001271已完成1 期
A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 2
研究概览
简要总结
Patients with CD22(+) B-cell lymphomas will be treated with escalating doses as a 192 hr infusion of immunotoxin in a Phase I study to determine dose limiting toxicity evidence of response.
详细描述
Patients with CD22(+) B-cell lymphomas will be treated with escalating doses as a 192 hr infusion of immunotoxin in a Phase I study to determine dose limiting toxicity evidence of response.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell MalignanciesB-Cell LymphomaLymphoma, Non-HodgkinLeukemia, Lymphocytic, B CellB-Cell LeukemiaAcute Lymphoid LeukemiaB-Non Hodgkin LymphomaB-NHLB-AllAcute Lymphocytic LeukemiaAcute Lymphoblastic LeukemiaNCT03448393National Cancer Institute (NCI)54
已完成
1 期
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell MalignanciesLarge Cell LymphomaALLB-AllB-precursor ALLAcute Lymphocytic LeukemiaB-Non Hodgkin LymphomaB-NHLNHLAcute Lymphoblastic LeukemiaFollicular LymphomaNCT02315612National Cancer Institute (NCI)134
招募中
1 期
A Phase 1 Study of BST02 in Treating Locally Advanced Liver CancerLocally Advanced Liver CarcinomaNCT06526832BioSyngen Pte Ltd9
已完成
1 期
BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's LymphomaLymphomaLeukemiaNCT00126646MedImmune LLC24
已完成
1 期
A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)Chronic Lymphocytic LeukemiaNCT00779883Memgen, LLC9